Investor Presentaiton

sanofi Significant direct medical costs in STI attributed to chlamydia Chlamydia next to HPV in terms of costs in STIs HBV $46 M HSV-2 $91 M Trichomoniasis $144 M Syphilis $174 M Gonorrhea Chlamydia HPV $271 M $691 M $775 M HIV $13.7 B Direct medical costs by infection in U.S. Griffith UNIVERSITY Queensland government in Australia fully recognizes the burden of disease in chlamydia Supporting our vaccine development through the Translational Science Hub in Queensland Queensland Government THE UNIVERSITY OF QUEENSLAND AUSTRALIA Source: CDC's Sexually Transmitted Disease Surveillance, 2021, sexually Transmitted Disease Surveillance, 2021, accessed May 10 101 Vaccines Investor Event

View entire presentation